Delayed-Release AKG Supplement Linked to 1.8 Years Younger Biological Age
A study of 4,260 health enthusiasts found delayed-release calcium-AKG was associated with measurably younger epigenetic age.
Summary
Researchers at the National University of Singapore analyzed saliva-based epigenetic data from over 4,000 health-conscious adults who completed detailed supplement and lifestyle questionnaires. Among 84 supplements tested, a delayed-release calcium-alpha-ketoglutarate formulation called Rejuvant was associated with a biological age roughly 1.8 years younger than expected, even after adjusting for age, sex, and smoking status. Standard AKG without the delayed-release formulation showed a much smaller, non-significant effect. CoQ10 also showed promise in longitudinal analysis, though results didn't survive multivariate correction. The study highlights the value of recruiting health enthusiast cohorts for supplement research and points to AKG and CoQ10 as candidates for future controlled trials.
Detailed Summary
Identifying which supplements actually slow biological aging is notoriously difficult. Most population studies lack the statistical power to detect effects because supplement use rates are too low or questionnaire data too coarse. This study tackled that problem by focusing on people who are already deeply invested in their health.
Researchers recruited 4,260 adults who had purchased at least one saliva-based DNA methylation test between 2020 and 2025. Participants completed detailed questionnaires covering supplement use, medications, and lifestyle factors. Biological age was measured using a proprietary 9-CpG epigenetic clock with a mean absolute error of 5.4 years, and results were expressed as an Age Residual — the difference between biological and chronological age.
The headline finding: users of Rejuvant, a delayed-release calcium-alpha-ketoglutarate plus vitamin formulation, had biological ages averaging 1.8 years younger than non-users. This association held up after adjusting for multiple confounders. Notably, participants taking regular, non-delayed-release AKG showed only a minimal, non-significant benefit, suggesting the delivery mechanism matters. Among medications, antihistamine use trended toward benefit, though sample sizes were too small to draw conclusions. CoQ10 showed favorable longitudinal associations, but these did not survive multivariate correction.
The practical implication is notable: the delivery format of a supplement — not just its active ingredient — may significantly influence outcomes. The AKG finding warrants replication in randomized controlled trials that can rule out healthy user bias.
Critical caveats apply. This is a cross-sectional, self-selected cohort of health enthusiasts, making healthy user bias a serious confound. People who buy epigenetic tests and take Rejuvant likely differ from the general population in many unmeasured ways. The epigenetic clock used is proprietary and relatively low-resolution. No causality can be established from this design, and the longitudinal subset findings were exploratory.
Key Findings
- Delayed-release calcium-AKG (Rejuvant) was associated with 1.8 years lower biological age after covariate adjustment.
- Standard AKG without delayed-release formulation showed no significant biological age benefit.
- CoQ10 was associated with improved epigenetic aging in longitudinal analysis, though not significant after correction.
- Antihistamine use trended toward lower biological age but was underpowered to reach significance.
- 71% supplement use rate in the cohort provided unusually high statistical power to detect supplement effects.
Methodology
Cross-sectional cohort of 4,260 self-selected health enthusiasts who completed saliva-based DNA methylation tests and detailed supplement questionnaires. Biological age was quantified via a proprietary 9-CpG epigenetic clock. Associations between 84 supplements and Age Residual were tested, with multivariate models adjusting for age, sex, smoking, and health status.
Study Limitations
The study is cross-sectional and relies on a self-selected cohort of health enthusiasts, introducing strong healthy user and recruitment bias. The epigenetic clock used is proprietary and based on only 9 CpG sites, limiting its resolution and independent validation. Full text was not available; this summary is based on the abstract only, so complete methodology and supplementary findings could not be reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.